Form 4: Verastem CEO Sells Shares for Tax Obligations

Verastem's President and CEO, Dan Paterson, sold 970 shares of common stock to cover tax withholding requirements related to restricted stock unit vesting.

Summary

• Dan Paterson, President and CEO of Verastem, Inc. and a Director, reported a sale of 970 shares of common stock.
• The transaction occurred on February 4, 2026, at a price of $6.69 per share.
• The sale was executed to satisfy statutory withholding requirements associated with the vesting of restricted stock units.
• Following this transaction, Paterson beneficially owns 612,919 shares of Verastem common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine, non-discretionary transaction for tax purposes, not a reflection of management's sentiment on the company's future performance.

Positives

• The sale is a routine, non-discretionary transaction for tax purposes, indicating the executive is receiving equity compensation.
• The transaction was pre-arranged under a Rule 10b5-1 plan, suggesting it is not based on new material non-public information.

Negatives

• A reduction in direct insider ownership, even for tax purposes, could be perceived as a minor negative by some investors.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it is a report of an insider transaction.

Industry Context

StockSavvy.ai notes that routine sales by executives to cover tax obligations upon restricted stock unit vesting are common across industries and generally not indicative of a change in management's confidence in the company's prospects. Such transactions are a standard part of executive compensation plans.

Comparison to Industry Standards

• This is a standard Form 4 filing for an executive's tax-related stock sale, a common occurrence among executives at publicly traded companies.
• Similar transactions are frequently observed at peer biotechnology or pharmaceutical companies where equity compensation is a significant component of executive remuneration.
• The volume of shares sold (970) is relatively small compared to the total beneficial ownership (612,919), which is typical for tax withholding purposes and does not suggest a significant divestment.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a small, non-discretionary sale for tax purposes. Generally understood as routine, though some may view any reduction in insider ownership negatively.
• Employees: No direct impact.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of a small number of shares by the CEO to cover tax obligations related to RSU vesting. Such transactions are common and do not typically signal a change in the company's fundamentals or management's outlook. Therefore, it provides no new information that would warrant a change in investment recommendation; a 'Hold' stance is appropriate unless other fundamental factors suggest otherwise.

Keywords

Verastem, VSTM, Dan Paterson, Form 4, insider trading, stock sale, CEO, restricted stock units, RSU, tax withholding, beneficial ownership, 10b5-1 plan